malaria vaccine

A malaria vaccine developed by researchers at the University of Maryland School of Medicine have been able to successfully induce, and maintain immunity, in over half their subjects. This development provides added hope for preventing malaria.
After thirty years of research, the British drug company GlaxoSmithKline announced that it is seeking the approval of the European Medicines Agency (EMA) for its anti-malaria vaccine, known as RTS,S.
A small-scale proof-of-concept study has given malaria researchers and the millions of victims of this ancient scourge reason for hope that an effective preventive vaccine may one day become a reality